Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109587" target="_blank" >RIV/00843989:_____/22:E0109587 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/22:A2302FTO

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.26529" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/ajh.26529</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ajh.26529" target="_blank" >10.1002/ajh.26529</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies

Popis výsledku v původním jazyce

Natural killer (NK) cells are part of a phylogenetically old defense system, which is characterized by its strong cytolytic function against physiologically stressed cells such as tumor cells and virus-infected cells. Their use in the treatment of hematological malignancies may be more advantageous in several ways when compared with the already established T lymphocyte-based immunotherapy. Given the different mechanisms of action, allogeneic NK cell products can be produced in a non-personal based manner without the risk of the formidable graft-versus-host disease. Advanced manufacturing processes are capable of producing NK cells relatively easily in large and clinically sufficient numbers, useable without subsequent manipulations or after genetic modifications, which can solve the lack of specificity and improve clinical efficacy of NK cell products. This review summarizes the basic characteristics of NK cells and provides a quick overview of their sources. Results of clinical trials in hematological malignancies are presented, and strategies on how to improve the clinical outcome of NK cell therapy are discussed.

Název v anglickém jazyce

Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies

Popis výsledku anglicky

Natural killer (NK) cells are part of a phylogenetically old defense system, which is characterized by its strong cytolytic function against physiologically stressed cells such as tumor cells and virus-infected cells. Their use in the treatment of hematological malignancies may be more advantageous in several ways when compared with the already established T lymphocyte-based immunotherapy. Given the different mechanisms of action, allogeneic NK cell products can be produced in a non-personal based manner without the risk of the formidable graft-versus-host disease. Advanced manufacturing processes are capable of producing NK cells relatively easily in large and clinically sufficient numbers, useable without subsequent manipulations or after genetic modifications, which can solve the lack of specificity and improve clinical efficacy of NK cell products. This review summarizes the basic characteristics of NK cells and provides a quick overview of their sources. Results of clinical trials in hematological malignancies are presented, and strategies on how to improve the clinical outcome of NK cell therapy are discussed.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American journal of hematology

ISSN

0361-8609

e-ISSN

1096-8652

Svazek periodika

97

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

16

Strana od-do

802-817

Kód UT WoS článku

000773282400001

EID výsledku v databázi Scopus

2-s2.0-85127266476